Prostate cancer is a major cause of disease and mortality among men, and each year 1.6
million men are diagnosed with and 366,000 men die of prostate cancer. In this review, we …

Metabolic reprogramming is central to malignant transformation and cancer cell growth. How
tumours use nutrients and the relative rates of reprogrammed pathways are areas of intense …

Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase
(HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of …

Altered lipid metabolism is increasingly recognized as a signature of cancer cells. Enabled
by label-free Raman spectromicroscopy, we performed quantitative analysis of lipogenesis …

Background A reduction in the availability of cholesterol may limit the cellular proliferation
required for cancer growth and metastasis. We tested the hypothesis that statin use begun …

Statins are competitive inhibitors of hydroxymethylglutaryl-CoA (HMG-CoA) reductase and
have been used to treat elevated low-density lipoprotein cholesterol (LDL-C) for almost four …

Cell signaling does not apparently occur randomly over the cell surface, but it seems to be
integrated very often into cholesterol-rich membrane domains, termed lipid rafts. Membrane …

Widespread prostate‐specific antigen (PSA) screening detects many cancers that would
have otherwise gone undiagnosed. To estimate the prevalence of unsuspected prostate …

Background The production of peroxide and superoxide is an inevitable consequence of
aerobic metabolism, and while these particular'reactive oxygen species'(ROSs) can exhibit a …

Purpose To evaluate the association between cumulative duration of metformin use after
prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with …